Treatment progress of severe aplastic anemia
10.3969/j.issn.1674-7445.2020.02.018
- VernacularTitle:重型再生障碍性贫血治疗进展
- Author:
Yanping JI
1
;
Zimin SUN
Author Information
1. Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
- Publication Type:Research Article
- Keywords:
Severe aplastic anemia;
Human leukocyte antigen;
Immunosuppressive therapy;
Haploidentical hematopoietic stem cell transplantation;
Overall survival;
Antithymocyte globulin;
Allogeneic hematopoietic stem cell transplantation;
Umbilical cord blood hematopoietic stem cell transplantation;
Graft-versus-host disease
- From:
Organ Transplantation
2020;11(2):293-
- CountryChina
- Language:Chinese
-
Abstract:
Severe aplastic anemia (SAA) is a rare type of bone marrow hematopoietic failure, which is associated with toxic T lymphocyte-based immune dysfunction, abnormal hematopoietic microenvironment and damage of hematopoietic stem cells in patients. SAA characterized by acute onset, rapid progression and high mortality rate, which requires rapid and stable recovery of the patients' hematopoietic function. In this article, the therapeutic progresses on immunosuppressive therapy (IST), sibling human leukocyte antigen (HLA)-matched allogenetic hematopoietic stem cell transplantation (allo-HSCT), replacement of donor hematopoietic stem cell transplantation and unrelated umbilical cord blood hematopoietic stem cell transplantation (UCBT) for SAA were reviewed.
